Supplemental Table 1. ApoM-induced Risk Ratios at DCCT Baseline and Closeout stratified by disease status and DCCT Randomized Treatment group.

Measure	Disease Progression (groups are not mutually exclusive)		
	Persistently Normal	**Macroalbuminuria**	**Chronic Kidney Disease**
INTENSIVE TREATMENT ARM	(n=180)	(n=12)	(n=7)
Overall	--	1.63 (1.03,2.59)	**2.15 (1.10, 4.19)**
Baseline DCCT	--	1.28 (0.68,2.39)	1.59 (0.94,2.69)
End of DCCT	--	**2.19 (1.14,4.19)**	**2.75 (1.05,7.22)**
STANDARD TREATMENT ARM	(n=149)	(n=38)	(n=19)
Overall	--	1.01 (0.85,1.20)	1.31 (1.00, 1.73)
Baseline DCCT	--	1.03 (0.80,1.31)	1.29 (0.79,2.13)
End of DCCT	--	1.01 (0.80,1.29)	1.35 (0.96,1.90)

Risk Ratios are adjusted for baseline disease cohort, sex, triglycerides, co measured eGFR, AER and the use of any ACE/ARB medications prior to disease progression.

Risk ratios are for a 1 standardized unit increase in ApoM and 95% confidence interval compared to persistently normal. The standard unit is measured in terms of a z-score.